Skip to content

Switching planner

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

Runs in your browser. What you enter stays on your device.

How this works

Most GLP-1 labels say nothing about switching from another GLP-1 medicine, and none gives a dose conversion between different drugs. A few labels do give instructions for moving between forms of the same drug. This planner shows exactly that and nothing more.

  • If the label of the medicine you are moving to has an instruction for your switch, you see it with the label's wording.
  • If it does not, you see the only starting dose that label states, and a note that the label is silent on switching.
  • When a label says two products shouldn't be used together, or aren't interchangeable milligram for milligram, you see that too.
  • The cost difference compares the cheapest verified way to pay for your current dose with the cheapest way to pay for the new medicine's starting dose.

It never converts a dose of one drug into a dose of another. Your prescriber makes that decision.

Label starting doses

First step of each label schedule
MedicineFormStarting doseMinimum time before increasing
FoundayoTablet (once daily)0.8 mg daily30 days
MounjaroKwikPen (multi-dose, 4 weekly doses)2.5 mg weekly28 days
MounjaroMulti-dose vial (4 weekly doses)2.5 mg weekly28 days
MounjaroSingle-dose pen2.5 mg weekly28 days
MounjaroSingle-dose vial2.5 mg weekly28 days
OzempicMulti-dose single-patient-use pen (4 weekly doses per pen at the maintenance dose; the 2 mg/3 mL pen delivers 4 doses of 0.25 mg plus 2 doses of 0.5 mg, or 4 doses of 0.5 mg)0.25 mg weekly28 days
OzempicTablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg)1.5 mg daily30 days
RybelsusTablet (once daily)3 mg daily30 days
SaxendaMulti-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens)0.6 mg daily7 days
TrulicitySingle-dose pen0.75 mg weekly28 days
WegovySingle-dose pen (7.2 mg pen is branded WEGOVY HD)0.25 mg weekly28 days
WegovyTablet (once daily)1.5 mg daily30 days
ZepboundKwikPen (multi-dose, 4 weekly doses)2.5 mg weekly28 days
ZepboundMulti-dose vial (4 weekly doses)2.5 mg weekly28 days
ZepboundSingle-dose pen2.5 mg weekly28 days
ZepboundSingle-dose vial2.5 mg weekly28 days

Every switching statement on the labels

Label statements about switching, combining and restarting
FromToWhat the label says
Foundayo Any other product The Foundayo label says using Foundayo together with another GLP-1 receptor agonist is not recommended.“Concomitant use with another GLP-1 receptor agonist is not recommended.”
Foundayo Tablet (once daily)Foundayo Tablet (once daily)If 7 or more consecutive daily doses of Foundayo are missed, the label says to reinitiate dosage escalation at a lower dosage. It does not say which lower dosage.“If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration (2.1), Warnings and Precautions (5.3), Adverse Reactions (6)].”
Mounjaro Mounjaro The Mounjaro label gives no dose conversion for changing between presentations (vial, pre-filled single-dose pen, KwikPen). It only says that if the prescribed presentation changes, the patient should be trained on the new one and consult its Instructions for Use.“Inform patients and their caregiver(s) which MOUNJARO presentation (e.g., vial, pre-filled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
Ozempic Multi-dose single-patient-use pen (4 weekly doses per pen at the maintenance dose; the 2 mg/3 mL pen delivers 4 doses of 0.25 mg plus 2 doses of 0.5 mg, or 4 doses of 0.5 mg)Ozempic Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg)The label says patients on the 0.5 mg dose of Ozempic injection may switch to Ozempic tablets, starting 4 mg or 9 mg once daily one week after stopping the injection. It gives no instruction for other Ozempic injection doses.“Patients taking the 0.5 mg dose of OZEMPIC injection may switch to OZEMPIC tablets. One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 4 mg or 9 mg of OZEMPIC tablets orally once daily.”
Ozempic Multi-dose single-patient-use pen (4 weekly doses per pen at the maintenance dose; the 2 mg/3 mL pen delivers 4 doses of 0.25 mg plus 2 doses of 0.5 mg, or 4 doses of 0.5 mg)Rybelsus Tablet (once daily)The label says patients on the 0.5 mg dose of Ozempic injection may switch to Rybelsus, starting 7 mg or 14 mg once daily one week after stopping the injection. It gives no instruction for other Ozempic injection doses.“Patients taking the 0.5 mg dose of OZEMPIC injection may switch to RYBELSUS tablets. One week after discontinuing 0.5 mg of subcutaneous OZEMPIC injection, start 7 mg or 14 mg of RYBELSUS orally once daily.”
Ozempic Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg)Rybelsus Tablet (once daily)The label says not to switch during the first 30 days (initiation phase). After that, Ozempic tablets 4 mg corresponds to Rybelsus 7 mg and Ozempic tablets 9 mg to Rybelsus 14 mg, and the new tablet is started the day after stopping the old one.“Do not switch between RYBELSUS and OZEMPIC tablets during the initiation phase (Days 1 to 30) [see Dosage and Administration (2.2)]. After 30 days of RYBELSUS or OZEMPIC tablet treatment (after the initiation phase) [see Dosage and Administration (2.2)], patients may switch between RYBELSUS and OZEMPIC tablet products (see Table 1). When switching between RYBELSUS and OZEMPIC tablets, initiate the other semaglutide tablet product the day after discontinuing the previous semaglutide tablet product.”
Rybelsus Tablet (once daily)Ozempic Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg)The shared Rybelsus and Ozempic tablets label says the two tablet products are not substitutable on a mg-to-mg basis, so a Rybelsus strength cannot be replaced with the same number of milligrams of Ozempic tablets, or the reverse.“RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.”
Rybelsus Tablet (once daily)Ozempic Tablet (once daily; shares a label with Rybelsus, not substitutable mg-to-mg)The label says not to switch during the first 30 days (initiation phase). After that, Rybelsus 7 mg corresponds to Ozempic tablets 4 mg and Rybelsus 14 mg to Ozempic tablets 9 mg, and the new tablet is started the day after stopping the old one.“Do not switch between RYBELSUS and OZEMPIC tablets during the initiation phase (Days 1 to 30) [see Dosage and Administration (2.2)]. After 30 days of RYBELSUS or OZEMPIC tablet treatment (after the initiation phase) [see Dosage and Administration (2.2)], patients may switch between RYBELSUS and OZEMPIC tablet products (see Table 1). When switching between RYBELSUS and OZEMPIC tablets, initiate the other semaglutide tablet product the day after discontinuing the previous semaglutide tablet product.”
Saxenda Any other product The Saxenda label says using Saxenda together with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended.“SAXENDA contains liraglutide. Coadministration with other liraglutide-containing products or with any other glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
Saxenda Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens)Saxenda Multi-dose single-patient-use pen, 18 mg per 3 mL pen (6 daily doses of 3 mg per pen; sold in cartons of 3 or 5 pens)If more than 3 days have passed since the last Saxenda dose, the label says to restart at 0.6 mg daily and follow the dosage escalation schedule again.“If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment.”
Wegovy Any other product The Wegovy label says using Wegovy tablets or Wegovy injection together with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.“Concomitant use of WEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.”
Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)The Wegovy label gives no dose conversion for changing between injection presentations (single-dose pen or syringe, FlexTouch pen). It only says that if the prescribed presentation changes, the patient should be trained on the new one and consult its Instructions for Use.“Inform patients and their caregiver(s) which WEGOVY presentation (e.g., single-dose pen or syringe, or WEGOVY FlexTouch single-patient-use pen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed WEGOVY presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)If 2 or more consecutive weekly doses of Wegovy injection are missed, the label says to reinitiate dosage escalation at a lower dosage. It does not say which lower dosage. The label gives no restart rule for Wegovy tablets.“If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration (2.2), Warnings and Precautions (5.6), Adverse Reactions (6.1)].”
Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)Wegovy Tablet (once daily)The Wegovy label says adults on the 2.4 mg weekly injection (for cardiovascular risk reduction or weight reduction) may switch to the 25 mg tablet, starting the 25 mg tablet once daily one week after stopping the 2.4 mg injection.“Patients taking WEGOVY 2.4 mg injection for cardiovascular risk reduction or weight reduction in adults may switch to WEGOVY 25 mg tablets. One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.”
Wegovy Tablet (once daily)Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)In the tablet dosing section, the Wegovy label says that if the 25 mg once-daily tablet maintenance dosage is not tolerated, a switch to the 1.7 mg once-weekly injection can be considered.“If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY injection 1.7 mg once weekly [see Dosage and Administration (2.5)].”
Wegovy Tablet (once daily)Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)The Wegovy label says patients on the 25 mg tablet may switch to the injection, starting 2.4 mg once weekly the day after stopping the tablets. For patients who do not tolerate the 25 mg tablet, it says to consider the 1.7 mg injection.“Patients may switch from WEGOVY 25 mg tablets to WEGOVY injection. The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly. For patients who do not tolerate WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection.”
Wegovy Tablet (once daily)Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)For patients with type 2 diabetes on the 25 mg Wegovy tablet who need additional weight reduction, the label says to consider switching to the 1.7 mg injection and then following the injection's dosage escalation.“If additional weight reduction is needed in patients with type 2 diabetes mellitus treated with WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection and follow the recommended dosage escalation for WEGOVY injection [see Dosage and Administration (2.2), Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].”
Wegovy Tablet (once daily)Wegovy Single-dose pen (7.2 mg pen is branded WEGOVY HD)The Wegovy label notes that some patients with type 2 diabetes may get subtherapeutic semaglutide blood concentrations on the tablets, and says to consider alternatives, including switching to the injection, if response to the tablets is inadequate.“Given the differences in average semaglutide blood concentrations after administration of WEGOVY tablets and WEGOVY injection, and the higher variability in semaglutide blood concentrations after administration of WEGOVY tablets in all patient populations, some patients with type 2 diabetes taking WEGOVY tablets may experience subtherapeutic semaglutide blood concentrations. In patients with type 2 diabetes with an inadequate response to WEGOVY tablets, consider alternative therapies, including switching to WEGOVY injection [see Dosage and Administration (2.5)].”
Zepbound Any other product The Zepbound label says using Zepbound together with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
Zepbound Zepbound The Zepbound label gives no dose conversion for changing between presentations (vial, prefilled single-dose pen, KwikPen). It only says that if the prescribed presentation changes, the patient should be trained on the new one and consult its Instructions for Use.“Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”

Frequently asked questions

Is there a dose conversion from Ozempic to Mounjaro?

The Mounjaro label gives no instructions for switching from another GLP-1 medicine; it only gives the starting dose (2.5 mg once weekly).

Source

How do I switch from the Wegovy injection to the Wegovy pill?

The Wegovy label says adults on the 2.4 mg weekly injection (for cardiovascular risk reduction or weight reduction) may switch to the 25 mg tablet, starting the 25 mg tablet once daily one week after stopping the 2.4 mg injection. Label text: "Patients taking WEGOVY 2.4 mg injection for cardiovascular risk reduction or weight reduction in adults may switch to WEGOVY 25 mg tablets. One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily."

Source

How do I switch from the Wegovy pill back to the injection?

The Wegovy label says patients on the 25 mg tablet may switch to the injection, starting 2.4 mg once weekly the day after stopping the tablets. For patients who do not tolerate the 25 mg tablet, it says to consider the 1.7 mg injection. Label text: "Patients may switch from WEGOVY 25 mg tablets to WEGOVY injection. The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly. For patients who do not tolerate WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection."

Source

Are Rybelsus and Ozempic tablets the same strength?

The shared Rybelsus and Ozempic tablets label says the two tablet products are not substitutable on a mg-to-mg basis, so a Rybelsus strength cannot be replaced with the same number of milligrams of Ozempic tablets, or the reverse. Label text: "RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis."

Source

What does the Zepbound label say about switching from another GLP-1?

The Zepbound label gives no instructions for switching from another GLP-1 medicine; it only gives the starting dose (2.5 mg once weekly).

Source

Can I take two GLP-1 medicines during the switch?

The Zepbound label says using Zepbound together with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. The Wegovy label says using Wegovy tablets or Wegovy injection together with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Label text: "ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended."

Source

Do I need to do anything when changing from a Zepbound pen to a vial or KwikPen?

The Zepbound label gives no dose conversion for changing between presentations (vial, prefilled single-dose pen, KwikPen). It only says that if the prescribed presentation changes, the patient should be trained on the new one and consult its Instructions for Use. Label text: "Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation."

Source

Sources (8)

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.